Dalton Announces U.S. FDA Approval of Clinical Trial Plan for Vaccine Against Campylobacter jejuni

Client Phase I clinical trial plan utilizing Dalton manufactured cGMP sterile conjugated vaccine approved by U.S. FDA. May 8, 2014 Dalton Pharma Services, a privately owned pharmaceutical services provider to leading pharmaceutical and biotechnology companies, today announced that Phase I clinical trial plan utilizing cGMP sterile conjugated vaccine against Campylobacter jejuni has been approved by the U.S. Food and Drug …